Cita APA (7a ed.)
Loizidis, S., Vogazianos, P., Kordatou, Z., Fotopoulos, G., Orphanos, G., Kyriakou, F., & Charalambous, H. (2025). Docetaxel and Ramucirumab as Subsequent Treatment After First-Line Immunotherapy-Based Treatment for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Study and Literature Review. Current Oncology, 32(11), 612-628.
Cita Chicago Style (17a ed.)
Loizidis, Sotiris, Paris Vogazianos, Zoe Kordatou, Georgios Fotopoulos, George Orphanos, Flora Kyriakou, y Haris Charalambous. "Docetaxel and Ramucirumab as Subsequent Treatment After First-Line Immunotherapy-Based Treatment for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Study and Literature Review." Current Oncology 32, no. 11 (2025): 612-628.
Cita MLA (9a ed.)
Loizidis, Sotiris, et al. "Docetaxel and Ramucirumab as Subsequent Treatment After First-Line Immunotherapy-Based Treatment for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Study and Literature Review." Current Oncology, vol. 32, no. 11, 2025, pp. 612-628.
Precaución: Estas citas no son 100% exactas.